Development of an advanced nanoformulation for the intracellular delivery of a caspase-3 selective activity-based probe

    Research output: Contribution to journalArticle

    Early online date

    View graph of relations

    The ability to label active caspase-3 represents a useful pharmacodynamic strategy to determine the efficacy of anti-tumour drugs. Activity-based probes (ABPs) provide a method for the labelling of activated caspases and the recent development of hybrid combinatorial substrate libraries (HyCoSuL) has allowed for the generation of highly selective ABPs to discriminately label these proteases. Here using this approach, a novel caspase-3 selective ABP (CS1) has been developed and validated in apoptotic cells to selectively bind caspase-3 over the closely related caspase-7. However, a critical bottleneck for ABPs is their cell penetrance and therefore this cell-impermeable CS1 probe was subsequently formulated into PLGA-based nanoparticles (CS1-NPs). We demonstrate the ability of these particles to be taken up by the cells and facilitate intracellular delivery of the ABP to effectively label caspase 3 in response to apoptotic stimuli. This work forms the foundation of a novel approach for the labelling of caspase 3 and may have downstream utility to measure real time apoptosis in tumours and other organs.

    Documents

    • Development of an advanced nanoformulation for the intracellular delivery of a caspase-3 selective activity-based probe

      Rights statement: © 2018 The Royal Society of Chemistry. This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms of use of the publisher.

      Accepted author manuscript, 890 KB, PDF-document

      Embargo ends: 13/12/2019

    DOI

    Original languageEnglish
    JournalNanoscale - Royal Society of Chemistry
    Journal publication date13 Dec 2018
    Early online date13 Dec 2018
    DOIs
    Publication statusEarly online date - 13 Dec 2018

    ID: 162244582